Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Common-Size Income Statement

Paying users area

Try for free

Regeneron Pharmaceuticals Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99, or

  • get full access to the entire website for at least 3 months from $62.19.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Regeneron Pharmaceuticals Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net product sales
Collaboration revenue
Other revenue
Revenues
Cost of goods sold
Cost of collaboration and contract manufacturing
Cost of revenues
Gross profit
Research and development
Acquired in-process research and development
Selling, general, and administrative
Other operating income (expense), net
Income from operations
Other income (expense), net
Interest expense
Other income (expense)
Income before income taxes
Income tax expense
Net income

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Regeneron Pharmaceuticals Inc. income from operations as a percentage of revenues decreased from 2021 to 2022 and from 2022 to 2023.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Regeneron Pharmaceuticals Inc. income before income taxes as a percentage of revenues decreased from 2021 to 2022 and from 2022 to 2023.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc. net income as a percentage of revenues decreased from 2021 to 2022 and from 2022 to 2023.